相关实验视频

Updated: Jul 31, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

对三阴性乳腺癌化疗敏感性的基因组指数

Ahammad Sameer C¹, Manan Shah², Dipayan Nandy²

¹Department of Applied Sciences, Parul University, Vadodara, India.

Asian Pacific journal of cancer prevention : APJCP

|June 28, 2023

概括

这项研究确定了与三阴性乳腺癌 (TNBC) 中的化疗耐药性相关的微RNA (miRNA). 一个基于miRNA调节的枢纽基因的新型化学抵抗指数 (CRI) 预测了TNBC患者的远程复发风险和生存益处.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
生物化学生物化学

背景情况:

三重阴性乳腺癌 (TNBC) 经常表现出化学疗法耐药性.
异常的微RNA (miRNA) 表达与TNBC中药物耐药性有关.
需要一种预后策略,将miRNA与化疗耐药性相关联.

研究的目的:

为了识别与乳腺癌化学抵抗相关的miRNAs.
开发基于miRNA调节基因的预后指数.
评估该指数与TNBC中远程复发风险的关联.

主要方法:

下载的miRNA微阵列数据集 GSE71142.2.
使用LIMMA识别了差异表达的miRNAs (DE-miRNAs).
预测了目标基因并进行了功能丰富分析.
构建了蛋白质-蛋白质相互作用网络,并确定了枢纽基因.
根据前六个枢纽基因定义的化学抵抗指数 (CRI).
使用相关性和考克斯模型评估CRI与远程复发风险的相关性.

主要成果:

选了12个DE-miRNA (六个上调,六个下调).
确定了上调的miRNAs (例如,miR-214-3p) 和下调的miRNAs (例如,miR-142-5p).
确定了对上调 (RAC1,MYC,CCND1) 和下调 (IL-6,SOCS1,PDGFRA) 小RNA 的顶部枢纽基因.
在CRI和远程复发风险之间发现了显著的关联.

结论:

开发的化学抵抗指数 (CRI) 与TNBC中远程复发风险有显著的关联.
CRI预测了生存益处,表明患者的危险率降低.
这种基于miRNA的指数为TNBC管理提供了潜在的预后策略.

关键词:

5 - - 甲酸是如何使用的化疗耐药性指数是指化疗耐药性指数.三阴性乳腺癌是三阴性乳腺癌.这就是miRNAs.

更多相关视频

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...